Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026
Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026
Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026
Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Fineline Cube May 27, 2026
Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Drug

AstraZeneca’s Strensiq Gains Approval for Rare Disease Therapy in Guangdong Under “Hong Kong-Macau Drug and Device Access”

Fineline Cube Aug 21, 2024

LONDON—AstraZeneca (NASDAQ: AZN, LON: AZN) , a leading UK-based pharmaceutical company, has announced that its...

Company Deals

Johnson & Johnson to Acquire Israel’s V-Wave Ltd. in a Deal Valued Up to $1.7 Billion

Fineline Cube Aug 21, 2024

NEW YORK—Johnson & Johnson (NYSE: JNJ), a multinational healthcare giant based in the US, has...

Policy / Regulatory

China’s National Drug Alliance Procurement Office Imposes Sanctions on Six Firms Over Collusion in Bromhexine Bidding

Fineline Cube Aug 21, 2024

BEIJING—The National Drug Alliance Procurement Office, which oversees the Volume-Based Procurement (VBP) program, has announced...

Company Medical Device

MicroPort MedTech’s ReeAmber Catheter Wins NMPA Nod for Peripheral Artery Treatments

Fineline Cube Aug 20, 2024

SHANGHAI—Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical device...

Company

CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus

Fineline Cube Aug 20, 2024

HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim...

Company

Genmab CEO Signals Potential for China Partnership as BioNTech Exits acasunlimab Collaboration

Fineline Cube Aug 20, 2024

COPENHAGEN—In a strategic pivot following BioNTech (NASDAQ: BNTX)’s withdrawal from their co-development partnership on the...

Company Drug

Hasten Biopharmaceutical Gains NMPA Nod for Somatostatin Marketing Rights in China

Fineline Cube Aug 20, 2024

BEIJING—Hasten Biopharmaceutical Co., Ltd, a biopharmaceutical company supported by the CBC Group, has received approval...

Company Drug

Yipinhong Pharmacy’s AR882 Earns FDA Fast-Track Status for Gout Treatment

Fineline Cube Aug 20, 2024

BEIJING—China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced that its novel drug AR882 has...

Company Deals

Sichuan Kelun Pharmaceutical’s H1 2024 Report Highlights MSD Collaboration Milestones

Fineline Cube Aug 20, 2024

CHENGDU—Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has released its financial report for the first...

Policy / Regulatory

NHSA Flags Concerns Over Pricing of MicroPort’s Castor Aortic Stent Graft System

Fineline Cube Aug 20, 2024

BEIJING—The National Healthcare Security Administration (NHSA) has issued an open letter expressing concerns over the...

Company Drug

Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment

Fineline Cube Aug 20, 2024

TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...

Company Drug

BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment

Fineline Cube Aug 20, 2024

FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...

Company Deals

Jiangsu Hengrui Pharmaceuticals Expands R&D Footprint with Jinan Innovation Zone Partnership

Fineline Cube Aug 20, 2024

JINAN—The management committee of the Jinan Innovation Zone has entered into a strategic partnership with...

Company Medical Device

China’s NMPA Grants Medical Device License to DaAn Gene’s Monkeypox Detection Kit

Fineline Cube Aug 20, 2024

GUANGZHOU—DaAn Gene Co., Ltd, a subsidiary of Sun Yat-sen University based in China (SHE: 002030),...

Company Deals

Genesis MedTech’s J-VALVE System Transfers to Edwards Lifesciences, Marking a New Era in Aortic Valve Treatment

Fineline Cube Aug 20, 2024

SINGAPORE—In a strategic move to strengthen its position in the global medical device market, Edwards...

Company Drug

Changchun High & New Technology Secures NMPA Approval for Turner Syndrome Treatment

Fineline Cube Aug 20, 2024

CHANGCHUN—Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading biopharmaceutical company in...

Company Drug

AstraZeneca’s Fasenra Secures NMPA Approval for Severe Eosinophilic Asthma Maintenance Therapy

Fineline Cube Aug 20, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has granted market approval for AstraZeneca (NASDAQ:...

Company Drug

Genmab’s Tepkinly/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments

Fineline Cube Aug 20, 2024

COPENHAGEN—Genmab A/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC)...

Company Deals

Multitude Therapeutics and Adcendo ApS Partner on Anti-TF ADC, Targeting Global Cancer Treatment

Fineline Cube Aug 20, 2024

SHANGHAI/COPENHAGEN—In a strategic move to bolster cancer treatment options, Shanghai-based medical technology company Multitude Therapeutics...

Company Medical Device

Lepu Medical Secures Approval for RECATCHOR Catheter, Enhancing Cardiovascular Procedures

Fineline Cube Aug 19, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Posts pagination

1 … 318 319 320 … 672

Recent updates

  • Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing
  • TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC
  • Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech
  • Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Company Drug

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.